Long-term Outcomes in the Chemo-free era for Acute Promyelocytic Leukemia (EHA2024)
Join us for an insightful lecture by Prof Maria Teresa Voso from University of Rome Tor Vergata in Italy, as she discusses the advances in the treatment of a rare subtype of AML, the acute promyelocytic leukemia (APL). As the PML::RARA rearrangement, resulting in a fusion protein that disrupts retinoic acid signaling and PML function, is the hallmark driver of APL, it is used as target for APL treatment.
Listen to Prof Voso as she talks about the scientific developments leading to significant improvements in clinical outcomes for patients with APL and the role of ATRA / ATO therapy, which…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.